RHHBY Roche Holding AG Loading... : Investor Sentiment and Bull/Bear Views

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
Time Author Thesis Company / ticker Signal Since call Position Source
18:39
Sep 18
r/biotech_stocks
Roche's tolerability profile positions it well in obesity.
Author claims Roche is underestimated, with petrelintide producing only ~10.7% mean weight loss but no vomiting or GI discontinuations at the maximally effective dose, and CT-388 showing 22.5% placebo-adjusted weight loss at 48 weeks. The mechanism is that the obesity market is shifting towards tolerability, convenience, maintenance, and combinations, positioning Roche for patients who cannot tolerate stronger GLP1s. The catalyst is planned combination work between petrelintide and CT-388. The main risk is that lower efficacy may limit adoption, though author frames it positively for a subset.
RHHBY Roche Holding AG Long 1ST — —
11:29
Sep 17
Bloomberg Markets
Roche lymphoma trial success boosts shares
Roche's late-stage lymphoma drug Lunsumio met its primary endpoint and slowed disease progression, with no conclusive survival data yet; the trial success could boost shares while Roche outperforms peers like Novartis, which has had trial setbacks.
RHHBY Roche Holding AG Long 1ST — —
12:06
Jul 23
Bloomberg Markets
Roche strong pipeline and growth.
Roche continues to grow well with 6% sales growth and 10% profit growth, trends toward the higher end of guidance, and has a strong pipeline including a transformational breast cancer pill with FDA priority review; the portfolio boasts 16 blockbuster medicines, reinforcing market leadership.
RHHBY Roche Holding AG Long 2ND — —
Log in to see ideas

About RHHBY Investor Commentary

Across the available history and selected sources, Buzzberg tracks RHHBY (Roche Holding AG) across 12 sources: 7 bullish vs 1 bearish calls from 22 authors. Historical directional balance: 16% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 37 total trade ideas tracked. Latest voices: u/fuckagriculture, Chloe Meley, Thomas Schinecker.